Abstract | BACKGROUND/AIMS: METHODOLOGY: Sixteen CRC patients with unresectable liver metastases were treated with concurrent HAI and systemic oral UFT/UZEL. Eligible patients were previously untreated (except for adjuvant therapy) CRC patients with unresectable liver metastases, with WHO performance statuses of 0 to 2. On an outpatient basis, the patients received a treatment regimen consisting of 5-fluorouracil at 1000 mg/m2 and l- Leucovorin at 50 mg/m2 for 5 hours on days 1, 8, 15, and 22 by hepatic arterial infusion plus oral UFT (300 mg/m2) and UZEL (75 mg/body) on days 2-7, 9-14, and 23-28 followed by withdrawal for one week. The cycles were repeated every 5 weeks until disease progression. RESULTS: A total of 103 cycles of HAI with the UFT/UZEL regimen were administered (median, 5 cycles; range, 6 to 9 cycles). The response rate was 87.5% (14 partial responses and 2 stable diseases). The median progression-free survival rate was 9.2 months, and the median survival time was 22 months. No treatment-related grade 3 or 4 adverse events were observed. CONCLUSIONS: This novel locoregional HAI with an oral UFT/UZEL systemic chemotherapeutic regimen is feasible in an outpatient setting and should be considered as first-line chemotherapy for CRC patients with unresectable liver metastases.
|
Authors | Soichi Tsutsumi, Satoru Yamaguchi, Kaori Tsuboi, Takaharu Fukasawa, Yuichi Tabe, Takayuki Asao, Hiroyuki Kuwano |
Journal | Hepato-gastroenterology
(Hepatogastroenterology)
2008 Jul-Aug
Vol. 55
Issue 85
Pg. 1419-22
ISSN: 0172-6390 [Print] Greece |
PMID | 18795703
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Vitamin B Complex
- Tegafur
- Uracil
- Leucovorin
|
Topics |
- Administration, Oral
- Adult
- Aged
- Ambulatory Care
- Antineoplastic Agents
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage)
- Colorectal Neoplasms
(pathology)
- Disease-Free Survival
- Female
- Humans
- Infusions, Intra-Arterial
- Leucovorin
(administration & dosage)
- Liver Neoplasms
(drug therapy, secondary)
- Male
- Middle Aged
- Tegafur
(administration & dosage)
- Treatment Outcome
- Uracil
(administration & dosage)
- Vitamin B Complex
(administration & dosage)
|